Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1432603
This article is part of the Research Topic Advances in Chemotherapy-Resistant Hepatocellular Carcinoma, Volume II View all 3 articles

Research Progress and Prospect of Postoperative Adjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma

Provisionally accepted
Guan Lianyue Guan Lianyue *Sun Yanxin Sun Sun Yanxin Sun Jiang Wei Jiang Wei Duan Ruiheng Duan Ruiheng
  • Department of Hepatopancreatobiliary Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, China

The final, formatted version of the article will be published soon.

    Intrahepatic cholangiocarcinoma (ICC) is the second most common primary malignancy of the liver, following hepatocellular carcinoma (HCC). Surgical resection remains the only potentially curative treatment for ICC. However, due to its high malignancy and propensity for postoperative recurrence, the prognosis for ICC is generally poor, and there is currently little standardized approach for adjuvant therapy following curative surgery. This article aims to explore adjuvant treatment strategies for ICC post-curative surgery by reviewing retrospective studies and clinical trials conducted in recent years. The analysis focuses on the effectiveness, challenges, and potential developments in the management of ICC post-surgery, considering the high recurrence rates and the need for improved therapeutic approaches to enhance patient outcomes. Additionally, we discuss the various types of adjuvant treatments that have been explored, including chemotherapy, radiation therapy, and targeted therapies. The goal is to provide a comprehensive overview of the current landscape and highlight promising directions for future research to improve survival and quality of life for ICC patients.

    Keywords: ：Intrahepatic cholangiocarcinoma, Surgery, Recurrence, adjuvant therapy, liver cancer, beneficiary population

    Received: 14 May 2024; Accepted: 29 Jul 2024.

    Copyright: © 2024 Lianyue, Yanxin Sun, Wei and Ruiheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Guan Lianyue, Department of Hepatopancreatobiliary Surgery, China-Japan Union Hospital of Jilin University, Changchun, 130033, Jilin Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.